Integra LifeSciences Holdings
$ 11.18
1.82%
11 Feb - close price
- Market Cap 855,460,000 USD
- Current Price $ 11.18
- High / Low $ 11.25 / 10.60
- Stock P/E N/A
- Book Value 13.33
- EPS -6.47
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.39 %
- 52 Week High 25.45
- 52 Week Low 10.60
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$15.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 | 2023-04-26 | 2023-02-22 |
| Reported EPS | 0.54 | 0.45 | -0.3308 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 | 0.74 | 0.94 |
| Estimated EPS | 0.43 | 0.44 | 0.4311 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 | 0.74 | 0.9 |
| Surprise | 0.11 | 0.01 | -0.7619 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 | 0 | 0.04 |
| Surprise Percentage | 25.5814% | 2.2727% | -176.7339% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% | 0% | 4.4444% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.8 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-02-10 03:28:27
Integra LifeSciences Holdings Corporation announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor relations website. Interested participants can register to receive dial-in details for the event.
2026-02-09 11:58:35
Integra LifeSciences Holdings Corporation will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens. Management will host a conference call at 8:30 a.m. ET, and a live webcast will be available on the company's investor relations website. A webcast replay will also be accessible after the call.
2026-01-23 11:28:47
The FDA has issued an alert regarding Integra LifeSciences' MediHoney Wound products, clarifying that they are not associated with MediWound. Integra LifeSciences operates in the medical device sector, focusing on regenerative therapy and neurosurgical applications. The company faces financial challenges, including negative margins and high leverage, despite strong institutional interest and recent insider buying.
2026-01-07 04:10:49
Integra LifeSciences Holdings C (IART) shows a potential upside of 23.41% despite mixed financial performance, including positive revenue growth but negative EPS and ROE. The company, which operates in the medical devices industry, has strong free cash flow and reinvests earnings, facing varied analyst sentiment with an average target price of $15.50. Technical indicators suggest an overbought condition, emphasizing the need for investors to monitor sector trends and company developments closely.
2026-01-06 01:09:39
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, providing broad access to their discussion on innovative treatment pathways in surgical, neurologic, and regenerative care. The company's participation highlights its standing in the medical technology sector and its commitment to engaging with investors.
2026-01-05 21:09:39
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of their presentation will be available on the company's investor relations website. Integra LifeSciences is a global medical technology company focused on surgical, neurologic, and regenerative care.
